Linagliptin/Metformin Stada

Active Ingredient:: Metformin Hydrochloride, Linagliptin
Origin:: EU

Linagliptin/Metformin Stada (Metformin Hydrochloride, Linagliptin)

Q: What is Linagliptin/Metformin Stada used for?

Linagliptin/Metformin Stada is indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose levels by combining a DPP‑4 inhibitor with metformin, providing improved glycaemic control when diet, exercise, or metformin alone are insufficient.

Q: How does Linagliptin work in the body?

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which increases the levels of incretin hormones GLP‑1 and GIP. These hormones stimulate insulin release in a glucose‑dependent manner and reduce glucagon secretion, thereby lowering post‑prandial blood glucose.

Q: What is the usual dose of Linagliptin/Metformin Stada?

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Q: Is Linagliptin/Metformin safe during pregnancy or breastfeeding?

The safety of Linagliptin/Metformin in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefits outweigh the potential risks, and the decision must be made by a qualified healthcare provider.

Q: How do I order Linagliptin/Metformin Stada from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Linagliptin/Metformin compare with other antidiabetic classes?

Compared with sulfonylureas, the Linagliptin/Metformin combination has a lower risk of hypoglycaemia and does not cause weight gain. Unlike GLP‑1 receptor agonists, it is an oral tablet, which may be preferred by patients who avoid injections.

Q: What are the storage requirements for Linagliptin/Metformin Stada?

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct light, and keep out of reach of children.

Q: How is Linagliptin/Metformin administered?

Linagliptin/Metformin is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed.

Q: What are the most serious risks associated with Linagliptin/Metformin?

The most serious risks include lactic acidosis, particularly in patients with severe renal impairment, and pancreatitis. Patients should be educated to seek immediate medical attention for sudden abdominal pain, persistent nausea, or signs of severe metabolic disturbance.

Q: Who should not use Linagliptin/Metformin Stada?

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to linagliptin, metformin, or any excipients, and those with a history of lactic acidosis should not use this medication. Contra‑indications must be confirmed by a healthcare professional.

Linagliptin, the active ingredient in Linagliptin/Metformin Stada, is a DPP‑4 inhibitor presented as a tablet for oral use. Together with metformin hydrochloride, it forms a fixed‑dose combination that treats type 2 diabetes mellitus in adults by improving glycaemic control. It is indicated for patients who require additional glycaemic control beyond metformin alone.

GNH India supplies Linagliptin/Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global markets and therapeutic.

Manufacturer / TM Owner

Stada Arzneimittel Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Linagliptin/Metformin is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycaemia.
Type 2 diabetes mellitus: improves overall glycaemic control when added to diet and exercise, either as monotherapy or in combination with other antidiabetic agents.
Inadequate control with metformin alone: provides additional reduction in HbA1c levels.
Adjunct to other oral agents: enhances the efficacy of sulfonylureas, SGLT2 inhibitors or insulin when combined.

How It Works

Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which raises endogenous incretin hormones (GLP‑1 and GIP) and thereby enhances glucose‑dependent insulin secretion while suppressing glucagon release. Metformin hydrochloride reduces hepatic gluconeogenesis, improves peripheral insulin sensitivity, and increases glucose uptake in muscle, collectively lowering blood glucose concentrations.

Side Effects

Common Side Effects

Nausea: mild to moderate gastrointestinal upset.
Diarrhoea: loose stools, usually transient.
Abdominal discomfort: cramps or bloating.
Headache: mild tension‑type headache.
Dizziness: occasional light‑headedness.
Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects

Lactic acidosis: rare but life‑threatening metabolic disturbance.
Pancreatitis: severe abdominal pain with elevated enzymes.
Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
Hepatic failure: signs of liver dysfunction.
Allergic reactions: rash, pruritus, or angio‑edema.
Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating therapy, evaluate patient-specific factors and monitor regularly.

Renal function: assess baseline eGFR and monitor periodically.
Hepatic function: evaluate liver enzymes in patients with known liver disease.
Lactic acidosis risk: avoid in patients with severe renal impairment or conditions predisposing to hypoxia.
Pregnancy and lactation: use only if potential benefit justifies the risk.
Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Linagliptin/Metformin may interact with several medicines; review concomitant therapy.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated.
Concurrent use with other DPP‑4 inhibitors: risk of additive effects.
Co‑administration with iodinated contrast media in patients with reduced renal function: avoid.

Moderate Interactions (Monitor Closely)

Metformin with cimetidine or trimethoprim: may increase metformin plasma levels; monitor renal function.
Linagliptin with strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin exposure; consider dose adjustment.

Frequently Asked Questions

Linagliptin/Metformin Stada is indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower blood glucose levels by combining a DPP‑4 inhibitor with metformin, providing improved glycaemic control when diet, exercise, or metformin alone are insufficient.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which increases the levels of incretin hormones GLP‑1 and GIP. These hormones stimulate insulin release in a glucose‑dependent manner and reduce glucagon secretion, thereby lowering post‑prandial blood glucose.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of Linagliptin/Metformin in pregnancy or while breastfeeding has not been fully established. It should only be used if the potential benefits outweigh the potential risks, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas, the Linagliptin/Metformin combination has a lower risk of hypoglycaemia and does not cause weight gain. Unlike GLP‑1 receptor agonists, it is an oral tablet, which may be preferred by patients who avoid injections.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct light, and keep out of reach of children.

Linagliptin/Metformin is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed.

The most serious risks include lactic acidosis, particularly in patients with severe renal impairment, and pancreatitis. Patients should be educated to seek immediate medical attention for sudden abdominal pain, persistent nausea, or signs of severe metabolic disturbance.

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to linagliptin, metformin, or any excipients, and those with a history of lactic acidosis should not use this medication. Contra‑indications must be confirmed by a healthcare professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.